FilingSEC EDGAR8-K
bioAffinity Reports Over 100% Growth in CyPath® Lung Sales
· SEC accepted
StageCommercialization
Filing content
Sales of the CyPath® Lung test increased by over 100% through Q3 2026 compared to 2025, driven by an 89% increase in ordering physicians and higher utilization.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…